{"id":398974,"date":"2020-12-14T08:33:24","date_gmt":"2020-12-14T13:33:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398974"},"modified":"2020-12-14T08:33:24","modified_gmt":"2020-12-14T13:33:24","slug":"cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/","title":{"rendered":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference"},"content":{"rendered":"

<\/p>\n

CEL-SCI Corporation to Present at the 13th<\/sup> Annual LD Micro Main Event Conference<\/b><\/p>\n

VIENNA, Va.–(BUSINESS WIRE<\/a>)–
\nCEL-SCI Corporation (NYSE American: CVM)<\/b>, a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 13th<\/sup> Annual LD Micro Main Event Conference on Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience.\n<\/p>\n

\nCEL-SCI\u2019s presentation will be broadcast live at https:\/\/ve.mysequire.com\/company?company_id=7413c04b-9bf8-491b-9f2a-88228de5695a<\/a> or on the Investor Relations section of CEL-SCI\u2019s website at cel-sci.com\/new-investor-information\/<\/a>.\n<\/p>\n

\nLD Micro\u2019s Main Event will feature a new format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.\n<\/p>\n

\nView CEL-SCI\u2019s profile here: http:\/\/www.ldmicro.com\/profile\/CVM<\/a><\/p>\n

About CEL-SCI Corporation<\/b><\/p>\n

\nCEL-SCI believes that boosting a patient\u2019s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine* first, BEFORE they received surgery, radiation and\/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and\/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.\n<\/p>\n

\nCEL-SCI believes that this Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study\u2019s protocol, newly diagnosed patients with advanced primary squamous cell carcinoma of the head and neck were treated with the Multikine treatment regimen right after diagnosis and prior to receiving the Standard of Care (SOC), which involves surgery, radiation or concurrent radiochemotherapy. Multikine is designed to help the immune system \u201csee\u201d the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body\u2019s immune system prior to SOC to attack the cancer. The Phase 3 study is fully enrolled with 928 patients and the last patient was treated in September 2016. To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 events have occurred among the two main comparator groups. This study milestone occurred in late April 2020. The study is currently in the statistical analysis phase.\n<\/p>\n

\nThe Company\u2019s LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment for COVID-19 infection. The Company has operations in Vienna, Virginia, and near\/in Baltimore, Maryland.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to Multikine and the Phase 3 clinical trial of Multikine in patients with advanced primary squamous cell carcinoma of the head and neck. When used in this press release, the words “intends,” “believes,” “anticipated,” “plans” and “expects,” and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical trials or nonclinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company’s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI’s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K\/A for the year ended September 30, 2019. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.\n<\/p>\n

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is in progress.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201214005103\/en\/<\/a><\/span><\/p>\n

\nGavin de Windt
\n
CEL-SCI Corporation
(703) 506-9460\n<\/p>\n

KEYWORDS:<\/b> United States North America District of Columbia Virginia<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Clinical Trials Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience. CEL-SCI\u2019s presentation will be broadcast live at https:\/\/ve.mysequire.com\/company?company_id=7413c04b-9bf8-491b-9f2a-88228de5695a or on the Investor Relations section of CEL-SCI\u2019s website at cel-sci.com\/new-investor-information\/. LD Micro\u2019s Main Event will feature a new format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts. View CEL-SCI\u2019s profile here: http:\/\/www.ldmicro.com\/profile\/CVM About … <\/p>\n

Continue reading “CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398974","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience. CEL-SCI\u2019s presentation will be broadcast live at https:\/\/ve.mysequire.com\/company?company_id=7413c04b-9bf8-491b-9f2a-88228de5695a or on the Investor Relations section of CEL-SCI\u2019s website at cel-sci.com\/new-investor-information\/. LD Micro\u2019s Main Event will feature a new format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts. View CEL-SCI\u2019s profile here: http:\/\/www.ldmicro.com\/profile\/CVM About … Continue reading "CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T13:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference\",\"datePublished\":\"2020-12-14T13:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/\"},\"wordCount\":856,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/\",\"name\":\"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-14T13:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/","og_locale":"en_US","og_type":"article","og_title":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference - Market Newsdesk","og_description":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience. CEL-SCI\u2019s presentation will be broadcast live at https:\/\/ve.mysequire.com\/company?company_id=7413c04b-9bf8-491b-9f2a-88228de5695a or on the Investor Relations section of CEL-SCI\u2019s website at cel-sci.com\/new-investor-information\/. LD Micro\u2019s Main Event will feature a new format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts. View CEL-SCI\u2019s profile here: http:\/\/www.ldmicro.com\/profile\/CVM About … Continue reading \"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T13:33:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference","datePublished":"2020-12-14T13:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/"},"wordCount":856,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/","name":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-14T13:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201214005103r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cel-sci-corporation-to-present-at-the-13th-annual-ld-micro-main-event-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398974"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398974\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}